trovafloxacin has been researched along with cefepime in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jolivette, LJ; Ward, KW | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Friedland, IR; Lutsar, I | 1 |
| Bonapace, CR; Bosso, JA; Friedrich, LV; White, RL | 1 |
| Calvo, A; García, R; Gómez-Lus, ML; Leturia, A; Sevillano, D; Valero, E | 1 |
| Borner, K; Brodersen, B; Koeppe, P; Lode, H; Lubasch, A; Ziege, S | 1 |
2 review(s) available for trovafloxacin and cefepime
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
New antibiotics.
Topics: Anti-Infective Agents; Cefepime; Cephalosporins; Child; Fluoroquinolones; Humans; Meningitis, Bacterial; Meropenem; Naphthyridines; Thienamycins | 1998 |
1 trial(s) available for trovafloxacin and cefepime
| Article | Year |
|---|---|
Serum bactericidal activity of trovafloxacin, in combination with cefepime or amikacin, in healthy volunteers.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Cefepime; Cephalosporins; Cross-Over Studies; Female; Fluoroquinolones; Humans; Male; Naphthyridines | 2003 |
6 other study(ies) available for trovafloxacin and cefepime
| Article | Year |
|---|---|
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with Etest, time-kill, and checkerboard methods.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Bacterial Agents; Anti-Infective Agents; Cefepime; Cephalosporins; Drug Synergism; Drug Therapy, Combination; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines; Penicillins; Piperacillin; Reproducibility of Results; Tobramycin | 2000 |
[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii].
Topics: Acinetobacter; Acinetobacter Infections; Ampicillin; Anti-Infective Agents; Aza Compounds; Cefepime; Cephalosporins; Ciprofloxacin; Colistin; Fluoroquinolones; Gatifloxacin; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Moxifloxacin; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Opportunistic Infections; Quinolines; Sulbactam; Thienamycins | 2001 |